Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Tel Aviv, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pituitary. 2018 Apr;21(2):168-175. doi: 10.1007/s11102-018-0865-7.
Non-functioning pituitary adenomas (NFPAs) are in general large tumors that present with symptoms secondary to local pressure on adjacent structures. Transsphenoidal surgery is the first line of treatment but residual tumor mass is often detected post-operatively. Medical therapy, in any stage of tumor management, is not well established.
A literature search was performed to review the available data on medical treatment of NFPAs.
Medications investigated for the treatment of NFPAs include dopamine receptor agonists (DA) and somatostatin receptor ligands. Randomized controlled trials are lacking, but available data suggest that DA have a positive effect on tumor remnant stabilization after surgery and could be considered in this setting. Temozolomide is reserved for aggressive tumors, although future studies are required.
NFPA are often not amenable to complete surgical resection. Conservative follow-up after surgery is associated with a high prevalence of tumor remnant progression. DA therapy may prevent residual tumor enlargement in over 85% of these patients, with a substantial consequent reduction in the need for repeat surgery or radiation therapy. It is our view that DA treatment should be routinely considered for the management of NFPA patients with incompletely resected tumors.
无功能性垂体腺瘤(NFPAs)通常为大型肿瘤,由于邻近结构受压而出现症状。经蝶窦手术是一线治疗方法,但术后常发现残留肿瘤。在肿瘤管理的任何阶段,药物治疗都尚未得到充分确立。
进行文献检索,以回顾关于 NFPAs 药物治疗的现有数据。
用于治疗 NFPAs 的药物包括多巴胺受体激动剂(DA)和生长抑素受体配体。目前缺乏随机对照试验,但现有数据表明,DA 对术后肿瘤残存量的稳定具有积极作用,在这种情况下可以考虑使用。替莫唑胺保留用于侵袭性肿瘤,但需要进一步研究。
NFPAs 通常不能完全通过手术切除。术后进行保守随访与肿瘤残存量进展的高发生率相关。DA 治疗可使超过 85%的此类患者的残留肿瘤不再增大,并显著减少重复手术或放射治疗的需求。我们认为,对于未完全切除肿瘤的 NFPAs 患者,应常规考虑 DA 治疗。